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after the tumor removal, starting irradiation after 3–5 days and keeping the tubes 10–12 days. Dose was 3–4Gy per fraction, twice
a day, 10 sessions if free surgical margin and 11 if affected. If the ﬁnal pathology showed positive nodes, fewer sessions were
administrated (5–6) and EBRT was added.
Results. Median follow-up was 28 months (1–115). There was local recurrence in 6 cases, with actuarial local control of 83% at 2
years (90% in pT1, 81.9% in pT2 and 66.3% in pT3). There were 6 cases of regional recurrence and distant metastasis in 3 cases.
Nine patients died, only 4 due to disease progression. The disease-free survival at 2 years was 73.6%, and cause-speciﬁc survival
was 89.4%. Acute complications were: one bleeding when removing the implant that required blood transfusion, lingual ulcer in
7 patients and severe mucositis in 2. Chronic complications were: 3 osteonecrosis and chronic lingual pain in 1 patient.
Conclusion. PIHB in carcinoma of the tongue is a technique with good local control and disease-free survival, with few acceptable
complications. It allows less aggressive surgery with better tongue functionality, greater accuracy when placing the implant,
higher doses with better dose distribution and earlier irradiation, avoiding surgical acts.
http://dx.doi.org/10.1016/j.rpor.2013.03.045
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Purpose. To evaluate the outcomes of patient (Pts) with low-risk-prostate-cancer treated with seeds monotherapy.
Material and methods. We reviewed retrospectively 700pts who had undergone transperineal-ultrasound-guided-implantation
with I-125-seeds as monotherapy between January 2000 and December 2012. All pts received 144/145Gy. The implant dose was
deﬁned as the dose delivered to 95% of the prostate volume. D90 was between 100% and 150%. The median f-up was 63 months
(range 6–164). 11pts were lost. Median age was 64.8 years (range 35–79). We have considered separately the local relapse as
biopsy-proved-tumor after seed implantation, or evidence of metastases, and elevation of the prostate-speciﬁc antigen level
beyond the nadir value plus 2ng/mL as biochemical failure.
Results. The Gleason-score (G) was less than 7 in 684pts (97.7%), G7 13pts (1.9%), and G8 3pts. 0.4%. The initial prostate-speciﬁc-
antigen (PSA) level was lower than 10ng/mL in 664pts (94.4%), 10.1–20 in 32pts (4.6%). The disease stage was up to T2a in 685pts
97.8%; T2b–T2c in 15 (2.2%). 85pts (12.1%) received hormonal ablation. Overall survival was 94% (CI 92–96) and 84% (CI 78–90)
at 5 and 10-year. The cause speciﬁc survival was 100% and 97% (CI 95–99) at 5 and 10 year. The disease free survival was 95%
(CI 93–97) and 86% (CI 80–92) at the 5 and 10 year. The 5 and 10-year biochemical disease-free were 95% (CI 93–97) and 85% (CI
79–91) respectively. The GII and GIII rectal acute toxicity were 2.3% (n=16) and 1.4%(n=10). The GII and GIII genitourinary acute
toxicity were 22.6% and 6.9%: 59pts needed urinary catheter (8.4%), 30pts needed urinary cistostomy (4.3%) and 17pts needed
TUR (2.4%). The GII and GIII rectal late toxicity were 1% (n=7) and 1.5% (n=11), the GII and GIII genitourinary late toxicity were
6.2% (n=44) and 3.2% (n=23). Only 3pts died for progression and 1 for toxicity.
Conclusion. Our results in prostate permanent seeds are similar to the expected ones in terms of efﬁcacy and secondary acute
and chronic side-effects.
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Purpose/objective. The main advantages of episcleral plaque brachytherapy in choroidal melanoma, compared to enucleation, are
the possibility of preserving vision and secondly organ preservation. Local control is relevant and it is associated with prolonged
survival. The objectives are: to evaluate tumor local control (LC), the safety of the procedure and to report treatment-related
complications.
Materials and methods. 100 consecutive patients with choroidal melanoma (59 females and 41 males) underwent treatment with
Iodine-125 (125I) or ruthenium-106 (106Ru) since July 2006. The mean age was 56.5 years. According to the COMS classiﬁcation,
19 small tumors, 64 medium and 17 were large ones. 65.55% of cases were localized in the temporal quadrants. The diagnosis
was based on the results of ophthalmoscopic and ultrasonographic examination, and all patients underwent metastatic workup.
For dosimetric purposes, a virtual simulator of the eyeball was used for extrapolation of ultrasound and fundoscopy imaging
